Ashkenazi A - Search Results

1

Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.

Roth W, Isenmann S, Naumann U, Kügler S, Bähr M, Dichgans J, Ashkenazi A, Weller M. Roth W, et al. Among authors: ashkenazi a. Biochem Biophys Res Commun. 1999 Nov 19;265(2):479-83. doi: 10.1006/bbrc.1999.1693. Biochem Biophys Res Commun. 1999. PMID: 10558893

2

APO2 ligand: a novel lethal weapon against malignant glioma?

Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M. Rieger J, et al. Among authors: ashkenazi a. FEBS Lett. 1998 May 1;427(1):124-8. doi: 10.1016/s0014-5793(98)00409-8. FEBS Lett. 1998. PMID: 9613612 Free article.

3

Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis.

Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bähr M, Ohgaki H, Ashkenazi A, Weller M. Roth W, et al. Among authors: ashkenazi a. Cancer Res. 2001 Mar 15;61(6):2759-65. Cancer Res. 2001. PMID: 11289159

4

Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice.

Naumann U, Bähr O, Wolburg H, Altenberend S, Wick W, Liston P, Ashkenazi A, Weller M. Naumann U, et al. Among authors: ashkenazi a. Gene Ther. 2007 Jan;14(2):147-61. doi: 10.1038/sj.gt.3302845. Epub 2006 Sep 7. Gene Ther. 2007. PMID: 16957768

5

A novel receptor for Apo2L/TRAIL contains a truncated death domain.

Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, Ashkenazi A. Marsters SA, et al. Among authors: ashkenazi a. Curr Biol. 1997 Dec 1;7(12):1003-6. doi: 10.1016/s0960-9822(06)00422-2. Curr Biol. 1997. PMID: 9382840 Free article.

6

Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.

Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, Ashkenazi A, de Vos AM. Hymowitz SG, et al. Among authors: ashkenazi a. Mol Cell. 1999 Oct;4(4):563-71. doi: 10.1016/s1097-2765(00)80207-5. Mol Cell. 1999. PMID: 10549288 Free article.

7

Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1.

Zhou Q, Fukushima P, DeGraff W, Mitchell JB, Stetler Stevenson M, Ashkenazi A, Steeg PS. Zhou Q, et al. Among authors: ashkenazi a. Cancer Res. 2000 May 15;60(10):2611-5. Cancer Res. 2000. PMID: 10825131

8

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Kischkel FC, et al. Among authors: ashkenazi a. Immunity. 2000 Jun;12(6):611-20. doi: 10.1016/s1074-7613(00)80212-5. Immunity. 2000. PMID: 10894161 Free article.

9

Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.

Pollack IF, Erff M, Ashkenazi A. Pollack IF, et al. Among authors: ashkenazi a. Clin Cancer Res. 2001 May;7(5):1362-9. Clin Cancer Res. 2001. PMID: 11350907

10

Apo2L/TRAIL and its death and decoy receptors.

LeBlanc HN, Ashkenazi A. LeBlanc HN, et al. Among authors: ashkenazi a. Cell Death Differ. 2003 Jan;10(1):66-75. doi: 10.1038/sj.cdd.4401187. Cell Death Differ. 2003. PMID: 12655296 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

566 results

Search Page

Filters